Anatara Lifesciences Limited (ANR:ASX) Investor Relations Material

Overview

Anatara Lifesciences Limited, based in Carlton, Australia, is a research and development company that focuses on evidence-based solutions for gastrointestinal diseases in both humans and animals. Its flagship product, Gastrointestinal ReProgramming (GaRP), is a proprietary formulation that targets primary underlying factors related to gastrointestinal conditions such as irritable bowel syndrome and inflammatory bowel disease. Additionally, the company has developed Detach, a treatment for diarrhea in piglets, and is working on bromelain-based formulations for piglets and poultry. Anatara Lifesciences Limited was founded in 2010.

Frequently Asked Questions

What is Anatara Lifesciences Limited's ticker?

Anatara Lifesciences Limited's ticker is ANR

What exchange is Anatara Lifesciences Limited traded on?

The company's shares trade on the ASX stock exchange

Where are Anatara Lifesciences Limited's headquarters?

They are based in Carlton, Australia

How many employees does Anatara Lifesciences Limited have?

There are 1-10 employees working at Anatara Lifesciences Limited

What is Anatara Lifesciences Limited's website?

It is https://anataralifesciences.com/

What type of sector is Anatara Lifesciences Limited?

Anatara Lifesciences Limited is in the Healthcare sector

What type of industry is Anatara Lifesciences Limited?

Anatara Lifesciences Limited is in the Biotechnology industry

Who are Anatara Lifesciences Limited's peers and competitors?

The following five companies are Anatara Lifesciences Limited's industry peers:

- Aduro BioTech Inc

- Verona Pharma plc

- Motus GI

- Fate Therapeutics

- Acorda Therapeutics